Status: Recruiting
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors. The CAR target antigen is selected for each participant after tumor profiling using a tissue biopsy and/or liquid biopsy. Participants will receive either a single-target or dual-target CAR-NK product based on the antigen profile.
Participants needed: 85
Trial details
Phase: Phase 1, Phase 2Age: 8-85Biological sex: AllType: InterventionalSponsor: Essen BiotechUpdated: Feb 18, 2026Locations: 1
Eligibility criteria
Age 18-75 years. [+8]
Prior treatment with gene-modified cellular therapy (e.g., CAR-T, CAR-NK) within... [+6]